"Geriatricizing" drug development - A Young International Society of Geriatric Oncology letter to the editor
- PMID: 36319551
- PMCID: PMC10701687
- DOI: 10.1016/j.jgo.2022.10.013
"Geriatricizing" drug development - A Young International Society of Geriatric Oncology letter to the editor
Conflict of interest statement
Conflict of interest/disclosure
None.
Comment on
-
Use of geriatric assessment in cancer clinical trials: A systematic review.J Geriatr Oncol. 2022 Sep;13(7):907-913. doi: 10.1016/j.jgo.2022.04.014. Epub 2022 May 9. J Geriatr Oncol. 2022. PMID: 35550351 Free PMC article.
References
-
- Lab M. COMOGRAM. http://comogram.org; 2019. accessed September 24th, 2022.
-
- IfKKIGaK Nordwest, Lösungen S-SuB, GmbH TAO, et al. Aflibercept and 5-FU vs. FOLFOX as 1st line treatment for elderly or frail elderly patients with met. Colorectal Cancer 2018. https://ClinicalTrials.gov/show/NCT03530267.
-
- Atezolizumab after chemo-radiotherapy for MIBC patients not eligible for radical cystectomy. https://ClinicalTrials.gov/show/NCT03697850; 2022.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
